Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial

Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial

Abstract Background MYC genes regulate ornithine decarboxylase (Odc) to increase intratumoral polyamines. We conducted a Phase I trial [NCT02030964] to determine the maximum tolerated dose (MTD) of DFMO, an Odc inhibitor, with celecoxib, cyclophosphamide and topotecan. Methods Patients 2–30 years of...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Michael D. Hogarty, David S. Ziegler, Andrea Franson, Yueh‐Yun Chi, Denice Tsao‐Wei, Kangning Liu, Rohan Vemu, Eugene W. Gerner, Elizabeth Bruckheimer, Anasheh Shamirian, Beth Hasenauer, Frank M. Balis, Susan Groshen, Murray D. Norris, Michelle Haber, Julie R. Park, Katherine K. Matthay, Araz Marachelian
Formatua: Artigo
Hizkuntza:ingelesa
Argitaratua: 2024
Sarrera elektronikoa:https://doi.org/10.1038/s41416-023-02525-2
https://www.nature.com/articles/s41416-023-02525-2.pdf
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Internet

https://doi.org/10.1038/s41416-023-02525-2
https://www.nature.com/articles/s41416-023-02525-2.pdf

Antzeko izenburuak